LEAF-4L6715

DRUG2 trials

Sponsors

Institut de cancérologie Strasbourg Europe, LEAF4Life, Inc.

Conditions

Acute Respiratory Distress SyndromeCOVID19, Sepsis or Other Causes

Phase 1

A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

CompletedNCT04378920

Institut de cancérologie Strasbourg EuropeAcute Respiratory Distress Syndrome, COVID19, Sepsis or Other Causes

Start: 2020-04-14End: 2021-08-24Updated: 2021-12-16

Phase 3

Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome

Not yet recruitingNCT06640777

LEAF4Life, Inc.Acute Respiratory Distress Syndrome

Start: 2024-11-01End: 2027-11-09Target: 310Updated: 2024-10-15

Related Papers

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.

2021-06-2415 citations